| Literature DB >> 28291589 |
David Dingli1, Sikander Ailawadhi2, P Leif Bergsagel3, Francis K Buadi4, Angela Dispenzieri4, Rafael Fonseca3, Morie A Gertz4, Wilson I Gonsalves4, Susan R Hayman4, Prashant Kapoor4, Taxiarchis Kourelis4, Shaji K Kumar4, Robert A Kyle4, Martha Q Lacy4, Nelson Leung5, Yi Lin4, John A Lust4, Joseph R Mikhael3, Craig B Reeder3, Vivek Roy2, Stephen J Russell4, Taimur Sher2, A Keith Stewart3, Rahma Warsame4, Stephen R Zeldenrust4, S Vincent Rajkumar4, Asher A Chanan Khan2.
Abstract
Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28291589 PMCID： PMC5554888 DOI： 10.1016/j.mayocp.2017.01.003
Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616